Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials

The Lancet

Volumn 388, Issue 10060, 2016, Pages 2629-2641

  Rodger, Marc A ^a   Gris, Jean Christophe ^b   de Vries, Johanna I P ^c   Martinelli, Ida ^d   Rey, Évelyne ^e   Schleussner, Ekkehard ^f   Middeldorp, Saskia ^g   Kaaja, Risto ^h   Langlois, Nicole J ^a   Ramsay, Timothy ^a   Mallick, Ranjeeta ^a   Bates, Shannon M ⁱ   Abheiden, Carolien N H ^c   Perna, Annalisa ^j   Petroff, David ^k   de Jong, Paulien ^l   van Hoorn, Marion E ^c   Bezemer, P Dick ^c   Mayhew, Alain D ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b Laboratoire d'Hematologie et Delegation A la Recherche Clinique et A l'Innovation   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF MONTREAL   (Canada)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF TURKU   (Finland)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k UNIVERSITY OF LEIPZIG   (Germany)

^l UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ALLERGIC REACTION; ANTEPARTUM HEMORRHAGE; ANTICOAGULANT THERAPY; ARTICLE; CAUCASIAN; DRUG FATALITY; FEMALE; FRAGILITY FRACTURE; GESTATIONAL AGE; HEPARIN INDUCED THROMBOCYTOPENIA; HETEROZYGOSITY; HUMAN; INTENTION TO TREAT ANALYSIS; MATERNAL DEATH; META ANALYSIS; MULTICENTER STUDY (TOPIC); PLACENTA; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK REDUCTION; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; SYSTEMATIC REVIEW; THROMBOPHILIA; TREATMENT RESPONSE; ADULT; COMPLICATION; NEWBORN; OBSTETRIC DELIVERY; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS;

ADULT; DELIVERY, OBSTETRIC; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOPHILIA;

EID: 84992360792     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31139-4     Document Type: Article

References (38)

1. 1 Centre for Maternal and Child Enquiries (CMACE). Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006–08. The eighth report on confidential enquiries into maternal deaths in the United Kingdom. BJOG 118:suppl 1 (2011), 1–203.
2. 2 Berg, CJ, Atrash, HK, Koonin, LM, Tucker, M, Pregnancy-related mortality in the United States, 1987–1990. Obstet Gynecol 88 (1996), 161–167.
3. 3 Stillbirth Collaboration Research Network Writing Group. Causes of death among stillbirths. JAMA 306 (2011), 2459–2468.
4. 4 van Rijn, BB, Hoeks, LB, Bots, ML, Franx, A, Bruinse, HW, Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 195 (2006), 723–728.
5. 5 Sibai, BM, Mercer, B, Sarinoglu, C, Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 165 (1991), 1408–1412.
6. 6 Van Oostwaard, MF, Langenveld, J, Schuit, E, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol 212 (2015), 624–717.
7. 7 Askie, LM, Duley, L, Henderson-Smart, DJ, Stewart, LA, Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369 (2007), 1791–1798.
8. 8 Bujold, E, Roberge, S, Lacasse, Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116 (2010), 402–414.
9. 9 Greer, IA, Nelson-Piercy, C, Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005), 401–407.
10. 10 Drewlo, S, Levytska, K, Sobel, M, Baczyk, D, Lye, SJ, Kingdom, JC, Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling. J Thromb Haemost 9 (2011), 2486–2497.
11. 11 Sobel, ML, Kingdom, J, Drewlo, S, Angiogenic response of placental villi to heparin. Obstet Gynecol 117 (2011), 1375–1383.
12. 12 de Vries, JIP, van Pampus, MG, Hague, WM, Bezemer, PD, Joosten, JH, Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 10 (2012), 64–72.
13. 13 Gris, JC, Chauleur, C, Molinari, N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 106 (2011), 1053–1061.
14. 14 Mello, G, Parretti, E, Fatini, C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 45 (2005), 86–91.
15. 15 Rey, E, Garneau, P, David, M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 7 (2009), 58–64.
16. 16 Gris, JC, Chauleur, C, Faillie, JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 104 (2010), 771–779.
17. 17 Martinelli, I, Ruggenenti, P, Cetin, I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 119 (2012), 3269–3275.
18. 18 Rodger, MA, Hague, WM, Kingdom, J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 384 (2014), 1673–1683.
19. 19 Visser, J, Ulander, VM, Helmerhorst, FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 105 (2011), 295–301.
20. 20 Kaandorp, SP, Goddijn, M, van der Post, JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 362 (2010), 1586–1596.
21. 21 Schleussner, E, Kamin, G, Seliger, G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med 162 (2015), 601–609.
22. 22 Clark, P, Walker, ID, Langhorne, P, et al. SPIN: the Scottish Pregnancy Intervention Study: a multicentre randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 115 (2010), 4162–4167.
23. 23 Rodger, MA, Carrier, M, Le Gal, G, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 123 (2014), 822–828.
24. 24 Rodger, MA, Langlois, NJ, de Vries, JI, et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Syst Rev, 3, 2014, 69.
25. 25 Giancotti, A, La, TR, Spagnuolo, A, et al. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. J Matern Fetal Neonatal Med 25 (2012), 1191–1194.
26. 26 Salman, SA, Shaaban, OM, Zahran, KM, Fathalla, MM, Anan, MA, Low molecular weight heparin (LMWH) for treatment of recurrent miscarriage negatively tested for antiphospholipid antibodies: a randomized controlled trial. Fertil Steril, 98, 2012, S191.
27. 27 Laskin, CA, Spitzer, KA, Clark, CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 36 (2009), 279–287.
28. 28 Higgins, JPT, Green, SE, Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March, 2011). Chapter 8: Assessing risk of bias in included studies. www.cochrane-handbook.org (accessed May 29, 2015).
29. 29 Rodger, MA, Walker, MC, Smith, GN, et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost 12 (2014), 469–478.
30. 30 Lykke, JA, Bare, LA, Olsen, J, et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost 10 (2012), 1320–1325.
31. 31 Sud, S, Douketis, J, The devil is in the details…or not? A primer on individual patient data meta-analysis. Evid Based Med 14 (2009), 100–101.
32. 32 Clarke, MJ, Individual patient data meta-analyses. Best Pract Res Clin Obstet Gynaecol 19 (2005), 47–55.
33. 33 Unverzagt, S, Prondzinsky, R, Peinemann, F, Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review. J Clin Epidemiol 66 (2013), 1271–1280.
34. 34 Dechartres, A, Boutron, I, Trinquart, L, Charles, P, Ravaud, P, Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med 155 (2011), 39–51.
35. 35 Wood, L, Egger, M, Gluud, LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336 (2008), 601–605.
36. 36 Moher, D, Pham, B, Jones, A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998), 609–613.
37. 37 Liddell, HS, Pattison, NS, Zanderigo, A, Recurrent miscarriage–outcome after supportive care in early pregnancy. Aust N Z J Obstet Gynaecol 31 (1991), 320–322.
38. 38 Musters, AM, Koot, YE, van den Boogaard, NM, et al. Supportive care for women with recurrent miscarriage: a survey to quantify women's preferences. Hum Reprod 28 (2013), 398–405.